Ye Liu
Chief Executive Officer bei OCUMENSION THERAPEUTICS
Vermögen: 22 Mio $ am 31.03.2024
Profil
Ye Liu is currently the Chief Executive Officer & Executive Director at Ocumension Therapeutics and also serves as a Director at EyePoint Pharmaceuticals, Inc. Prior to his current roles, he served as Chairman & General Manager at Santen Pharmaceutical (China) Co. Ltd., General Manager at Eisai China, Inc., and Head-Sales at Sandoz (China) Pharmaceutical Co., Ltd.
Mr. Liu received his graduate degree from Dalhousie University in 2003 and his undergraduate degree from Zhongshan Hospital Fudan University in 1993.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OCUMENSION THERAPEUTICS
4,37% | 10.01.2024 | 30 384 480 ( 4,37% ) | 22 Mio $ | 31.03.2024 |
Aktive Positionen von Ye Liu
| Unternehmen | Position | Beginn |
|---|---|---|
| OCUMENSION THERAPEUTICS | Chief Executive Officer | 01.08.2018 |
| EYEPOINT PHARMACEUTICALS, INC. | Director/Board Member | 01.01.2021 |
Ehemalige bekannte Positionen von Ye Liu
| Unternehmen | Position | Ende |
|---|---|---|
| Santen Pharmaceutical (China) Co. Ltd. | Chief Executive Officer | 01.07.2018 |
Eisai China, Inc.
 Eisai China, Inc. Pharmaceuticals: MajorHealth Technology Eisai China, lnc. engages in the manufacture of pharmaceutical products. It offers medicines for digestive, endocrine, orthopedic, and cancer diseases. The company was founded on March 28, 1996 and is headquartered in Suzhou, China. | Chief Executive Officer | 01.09.2014 |
Sandoz (China) Pharmaceutical Co., Ltd.
 Sandoz (China) Pharmaceutical Co., Ltd. Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz (China) Pharmaceutical Co., Ltd. is a global leader in generic pharmaceuticals and biosimilars. The private company is based in Shanghai, China. Sandoz is dedicated to helping patients increase drug accessibility and providing high-quality, affordable healthcare services to more patients worldwide. Founded in 2007, the Chinese company's purpose is to explore new methods of improving and extending people's lives. | Sales & Marketing | 01.02.2009 |
Ausbildung von Ye Liu
| Dalhousie University | Graduate Degree |
| Zhongshan Hospital Fudan University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| EYEPOINT PHARMACEUTICALS, INC. | Health Technology |
| OCUMENSION THERAPEUTICS | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| Santen Pharmaceutical (China) Co. Ltd. | |
Eisai China, Inc.
Eisai China, Inc. Pharmaceuticals: MajorHealth Technology Eisai China, lnc. engages in the manufacture of pharmaceutical products. It offers medicines for digestive, endocrine, orthopedic, and cancer diseases. The company was founded on March 28, 1996 and is headquartered in Suzhou, China. | Health Technology |
Sandoz (China) Pharmaceutical Co., Ltd.
Sandoz (China) Pharmaceutical Co., Ltd. Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz (China) Pharmaceutical Co., Ltd. is a global leader in generic pharmaceuticals and biosimilars. The private company is based in Shanghai, China. Sandoz is dedicated to helping patients increase drug accessibility and providing high-quality, affordable healthcare services to more patients worldwide. Founded in 2007, the Chinese company's purpose is to explore new methods of improving and extending people's lives. | Health Technology |
